| NCT05329545 | III | High grade serous NaPi2b+ ovarian cancer with platinum-sensitive recurrence and CR, PR or SD in most recent platinum-based therapy; no avastin with most recent platinum-based therapy (maintenance) | A Phase 3, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Upifitamab Rilsodotin (XMT-1536) as Post-Platinum Maintenance Therapy for Participants With Recurrent, Platinum-Sensitive, Ovarian Cancer (UP-NEXT) | AZ, CA, CO, FL, GA, IL, LA, ME, MD, MI, MN, MO, MT, NE, NV, NJ, NM, NY, NC, OH, OK, OR, PA, RI, SD, TN, TX, VA, WI | View Drugs | View Results |
| NCT05445778 | III | High grade serous FRalpha high+ ovarian cancer with platinum-sensitive recurrence and CR, PR or SD after second line platinum-based therapy, must have avastin with most recent platinum-based therapy (maintenance) | Randomized, Multicenter, Open-label, Phase 3 Study of Mirvetuximab Soravtansine in Combination With Bevacizumab Versus Bevacizumab Alone as Maintenance Therapy for Patients With FRĪ±-positive Recurrent Platinum-sensitive Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancers Who Have Not Progressed After Second Line Platinum-based Chemotherapy Plus Bevacizumab | LA, NV, NY, NC | View Drugs | View Results |
